Safety and efficacy of chidamide for maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with T-ALL/T-LBL

Post-transplant relapse remains a primary obstacle to long-term survival in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL), underscoring the need for effective maintenance therapies. Although chidamide, a selective histone deacetylase inhibitor, has shown activity in T-cell malignancies, its role as post-transplant maintenance has been scarcely studied. To evaluate the efficacy and safety of chidamide as maintenance therapy in T-ALL/T-LBL patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively analyzed 75 T-ALL/T-LBL patients who underwent allo-HSCT (December 2019-January 2024). Thirty-eight patients received chidamide-based maintenance, and 37 served as controls (no maintenance or non-chidamide regimens). The primary endpoints were overall survival (OS) and progression-free survival (PFS); safety endpoints included graft-versus-host disease (GVHD) incidence and treatment-related adverse events. Chidamide maintenance was associated with significantly improved OS and PFS compared with the non-chidamide group (OS: p = 0.001; PFS: p = 0.006). Multivariate Cox regression identified chidamide maintenance (OS: p = 0.003; PFS: p = 0.006) and complete remission status before transplantation (OS: p = 0.013; PFS: p = 0.012) as independent favorable prognostic factors. Chidamide did not increase acute GVHD; chronic GVHD was numerically higher (26.32% vs. 13.51%) but mostly mild to moderate and manageable. Adverse events were primarily hematologic toxicity (bone marrow suppression) and gastrointestinal, generally manageable and rarely required treatment discontinuation. Chidamide maintenance after allo-HSCT significantly improves survival outcomes in T-ALL/T-LBL patients with an acceptable safety profile, while pre-transplant remission status further refines prognosis. Prospective studies are warranted to confirm these findings and optimize maintenance strategies in this setting.

Authors

Institutions

Publication Details

Journal
Annals of Hematology
Published
2026-05-09
DOI
https://doi.org/10.1007/s00277-026-07016-x
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and efficacy of chidamide for maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with T-ALL/T-LBL

Xianling Chen, Kuangfei Wang, Xiaohui Lai, Ping Chen et al.
Annals of Hematology
Acute Lymphoblastic Leukemia research
article

Safety and efficacy of chidamide for maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with T-ALL/T-LBL

Xianling Chen, Kuangfei Wang, Xiaohui Lai, Ping Chen, Xiaojing Li, Xiaofan Li, Xiaohong Yuan, Nainong Li
article en

Abstract

Post-transplant relapse remains a primary obstacle to long-term survival in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL), underscoring the need for effective maintenance therapies. Although chidamide, a selective histone deacetylase inhibitor, has shown activity in T-cell malignancies, its role as post-transplant maintenance has been scarcely studied. To evaluate the efficacy and safety of chidamide as maintenance therapy in T-ALL/T-LBL patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively analyzed 75 T-ALL/T-LBL patients who underwent allo-HSCT (December 2019-January 2024). Thirty-eight patients received chidamide-based maintenance, and 37 served as controls (no maintenance or non-chidamide regimens). The primary endpoints were overall survival (OS) and progression-free survival (PFS); safety endpoints included graft-versus-host disease (GVHD) incidence and treatment-related adverse events. Chidamide maintenance was associated with significantly improved OS and PFS compared with the non-chidamide group (OS: p = 0.001; PFS: p = 0.006). Multivariate Cox regression identified chidamide maintenance (OS: p = 0.003; PFS: p = 0.006) and complete remission status before transplantation (OS: p = 0.013; PFS: p = 0.012) as independent favorable prognostic factors. Chidamide did not increase acute GVHD; chronic GVHD was numerically higher (26.32% vs. 13.51%) but mostly mild to moderate and manageable. Adverse events were primarily hematologic toxicity (bone marrow suppression) and gastrointestinal, generally manageable and rarely required treatment discontinuation. Chidamide maintenance after allo-HSCT significantly improves survival outcomes in T-ALL/T-LBL patients with an acceptable safety profile, while pre-transplant remission status further refines prognosis. Prospective studies are warranted to confirm these findings and optimize maintenance strategies in this setting.

Annals of Hematology
Fujian Medical University (CN), Fujian Provincial Hospital (CN), Union Hospital (CN)
National Key Clinical Specialty Discipline Construction Program of China, Fujian Provincial Health Technology Project
Good health and well-being
Openalex Percentile: Top 6%
Acute Lymphoblastic Leukemia research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.